Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H18N3O10.Gd.2H |
Molecular Weight | 547.57 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O
InChI
InChIKey=IZOOGPBRAOKZFK-UHFFFAOYSA-K
InChI=1S/C14H23N3O10.Gd/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3
Molecular Formula | C14H20N3O10 |
Molecular Weight | 390.3227 |
Charge | -3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Gd |
Molecular Weight | 157.25 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
CNS Activity
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7960618http://www.prnewswire.com/news-releases/fda-approves-dotarem-gadoterate-meglumine-first-macrocyclic-and-ionic-gadolinium-based-contrast-agent-in-usa-199354771.html
Curator's Comment: # Schering AG (now subsidiary of Bayer)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/31179770 |
105.0 mM [Ki] | ||
Target ID: P52209 Gene ID: 5226.0 Gene Symbol: PGD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20235752 |
73.0 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | DOTAREM Approved UseIndicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Launch Date2013 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date2011 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date2011 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date2011 |
PubMed
Title | Date | PubMed |
---|---|---|
Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. | 1997 May |
|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
Inhibition of transiently expressed low- and high-voltage-activated calcium channels by trivalent metal cations. | 2002 Jun 1 |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
Gadolinium-containing contrast media for radiographic examinations: a position paper. | 2002 Oct |
|
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. | 2004 May |
|
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. | 2005 Apr 20 |
|
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. | 2008 Apr |
|
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency. | 2009 Dec |
|
Release of ATP from rat urinary bladder mucosa: role of acid, vanilloids and stretch. | 2009 Dec |
|
Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity. | 2010 Aug |
|
Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal culture. | 2010 Mar |
|
Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. | 2010 Nov |
|
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. | 2011 Feb 18 |
|
Heavy metal cations permeate the TRPV6 epithelial cation channel. | 2011 Jan |
|
Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. | 2013 Apr |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:50 GMT 2025
by
admin
on
Mon Mar 31 18:21:50 GMT 2025
|
Record UNII |
K2I13DR72L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV08CA01
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
||
|
NDF-RT |
N0000180184
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
||
|
NCI_THESAURUS |
C62358
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
||
|
WHO-ATC |
V08CA01
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
||
|
NDF-RT |
N0000175862
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GADOPENTETIC ACID
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
100000085029
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
C87737
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
m5627
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB00789
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
5396
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200431
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
157429
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
DTXSID701001301
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
80529-93-7
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
SUB07864MIG
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY | |||
|
K2I13DR72L
Created by
admin on Mon Mar 31 18:21:50 GMT 2025 , Edited by admin on Mon Mar 31 18:21:50 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |